Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

Anti-cancer vaccine therapy for hematologic malignancies: An evolving era

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma